Chu‐Bin Luo

1.4k total citations
26 papers, 972 citations indexed

About

Chu‐Bin Luo is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Chu‐Bin Luo has authored 26 papers receiving a total of 972 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Chu‐Bin Luo's work include Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers), MicroRNA in disease regulation (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Chu‐Bin Luo is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers), MicroRNA in disease regulation (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Chu‐Bin Luo collaborates with scholars based in China, Ethiopia and India. Chu‐Bin Luo's co-authors include Zheng‐Jun Zhou, Shao‐Lai Zhou, Zhiqiang Hu, Haoyang Xin, Jia Fan, Xiaowu Huang, Jian Zhou, Ya Cao, Jian Zhou and Rongqi Sun and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Hepatology.

In The Last Decade

Chu‐Bin Luo

26 papers receiving 967 citations

Peers

Chu‐Bin Luo

ONCOL

IMMUN

SURGE

Markus Grubinger Austria

Longzi Liu China

Rongfa Yuan China

Su-Su Zheng China

Rindert Missiaen United States

Fengkai Xu China

Nadia Coltella Italy

Xing-Juan Yu China

Jianbo Zhang China

Zhenqun Xu China

Markus Grubinger Austria

Chu‐Bin Luo

531 ×1.0

214 ×0.5

344 ×1.2

ONCOL

180 ×0.7

IMMUN

73 ×0.4

SURGE

Citations per year, relative to Chu‐Bin Luo Chu‐Bin Luo (= 1×) peers Markus Grubinger

Countries citing papers authored by Chu‐Bin Luo

Since Specialization

Citations

This map shows the geographic impact of Chu‐Bin Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chu‐Bin Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chu‐Bin Luo more than expected).

Fields of papers citing papers by Chu‐Bin Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chu‐Bin Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chu‐Bin Luo. The network helps show where Chu‐Bin Luo may publish in the future.

Co-authorship network of co-authors of Chu‐Bin Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Chu‐Bin Luo. A scholar is included among the top collaborators of Chu‐Bin Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chu‐Bin Luo. Chu‐Bin Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Yawen, et al.. (2025). Epacadostat Overcomes Cetuximab Resistance in Colorectal Cancer by Targeting IDO‐Mediated Tryptophan Metabolism. Cancer Science. 116(6). 1715–1729. 3 indexed citations

Zhou, Zheng‐Jun, Zhiqiang Hu, Yayi Hou, et al.. (2024). Whole-exome sequencing reveals genomic landscape of intrahepatic cholangiocarcinoma and identifies SAV1 as a potential driver. Nature Communications. 15(1). 9960–9960. 4 indexed citations

Xin, Haoyang, Ning Li, Si-Yuan Pan, et al.. (2024). Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma. Clinical and Molecular Hepatology. 30(4). 914–928. 1 indexed citations

Xin, Haoyang, Rongqi Sun, Zhiqiang Hu, et al.. (2024). Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma. Journal of Gastroenterology. 59(5). 411–423. 8 indexed citations

Zhou, Shao‐Lai, Zheng‐Jun Zhou, Chengli Song, et al.. (2022). Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence. Signal Transduction and Targeted Therapy. 7(1). 24–24. 22 indexed citations

Luo, Chu‐Bin, Haoyang Xin, Zheng‐Jun Zhou, et al.. (2022). Tumor‐derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression. Hepatology. 76(4). 982–999. 78 indexed citations

Luo, Chu‐Bin, Haoyang Xin, Tong‐Chun Xue, et al.. (2022). The role of tumor-infiltrating B cells in the tumor microenvironment of hepatocellular carcinoma and its prognostic value: a bioinformatics analysis. Journal of Gastrointestinal Oncology. 13(4). 1959–1966. 7 indexed citations

Luo, Chu‐Bin, Haoyang Xin, Dan Yin, et al.. (2021). Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma. Aging. 13(11). 15126–15138. 12 indexed citations

Zhou, Shao‐Lai, Chu‐Bin Luo, Chengli Song, et al.. (2021). Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma. Hepatology. 75(4). 831–846. 13 indexed citations

10.

Zhou, Shao‐Lai, Haoyang Xin, Rongqi Sun, et al.. (2021). Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. JAMA Surgery. 157(1). 59–59. 39 indexed citations

11.

Hu, Zhiqiang, Haoyang Xin, Chu‐Bin Luo, et al.. (2020). Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma. Cancer Immunology Immunotherapy. 70(2). 377–389. 31 indexed citations

12.

Hu, Zhiqiang, Zheng‐Jun Zhou, Chu‐Bin Luo, et al.. (2020). Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resection. Cancer Cell International. 20(1). 582–582. 20 indexed citations

13.

Zhou, Zheng‐Jun, Chu‐Bin Luo, Haoyang Xin, et al.. (2020). MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3β/β-catenin signaling. npj Genomic Medicine. 5(1). 15–15. 14 indexed citations

14.

Zhou, Shao‐Lai, Zheng‐Jun Zhou, Zhiqiang Hu, et al.. (2019). Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. Journal of Hepatology. 71(6). 1152–1163. 54 indexed citations

15.

Hu, Jinwu, Zhangfu Yang, Jia Li, et al.. (2019). TGM3 promotes epithelial–mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection. Digestive and Liver Disease. 52(6). 668–676. 17 indexed citations

16.

Zhou, Zheng‐Jun, Haoyang Xin, Jia Li, et al.. (2019). Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection. Cancer Immunology Immunotherapy. 68(8). 1223–1233. 51 indexed citations

17.

Luo, Chu‐Bin, Dan Yin, Hao Zhan, et al.. (2018). microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A. Cell Death and Disease. 9(5). 535–535. 40 indexed citations

18.

Zhan, Hao, Qi‐Man Sun, Ai‐Wu Ke, et al.. (2017). Whole-Exome Sequencing-Based Mutational Profiling of Hepatitis B Virus-Related Early-Stage Hepatocellular Carcinoma. Gastroenterology Research and Practice. 2017. 1–7. 14 indexed citations

19.

Zhan, Hao, Jiahao Jiang, Chu‐Bin Luo, et al.. (2016). Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance. Tumor Biology. 37(7). 9691–9698. 21 indexed citations

20.

Hu, Zhiqiang, Shao‐Lai Zhou, Zheng‐Jun Zhou, et al.. (2016). Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection. Oncotarget. 7(32). 51733–51746. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact